호흡곤란 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.4%로 성장할 전망이며, 89억 7,000만 달러로 성장이 예측됩니다. 예측 기간 동안 성장은 만성질환 유병률 증가, 맞춤형 의료에 대한 수요 증가, 오염 수준 악화, 원격의료 채택 확대, 보다 유리한 규제 시행 등에 기인할 것으로 보입니다. 예측 기간 주요 동향으로는 전략적 제휴, 기술의 진보, 신규 흡입기의 개발, 개별화 의료의 확대, 표적 요법의 대두 등을 들 수 있습니다.
호흡기 질환의 유병률 상승은 향후 수년간 호흡곤란 시장의 성장을 견인할 것으로 예측됩니다. 호흡기 질환은 폐나 호흡기 계통의 다른 부분에 영향을 미쳐 호흡곤란과 산소 교환 장애를 일으킵니다. 일반적인 질환에는 천식, 만성폐쇄성폐질환(COPD), 결핵 등이 있습니다. 호흡기 질환의 증가는 대기오염, 흡연, 환경독소 노출, 기후변화 등의 요인에 의한 것입니다. 호흡곤란은 폐기능장애를 나타내고 치료 전략을 도출하며 질환의 진행을 감시함으로써 호흡기 질환의 진단 및 관리에 중요한 역할을 합니다. 예를 들어 2023년 11월 호주를 거점으로 한 비영리단체 National Asthma Council은 2022년 호주에서 467명의 천식 관련사가 기록돼 여성 299명, 남성 168명을 포함하며 2021년 355명에서 증가했다고 보고했습니다. 그 결과 호흡기 질환의 유병률 증가가 호흡곤란 시장 확대에 박차를 가하고 있습니다.
헬스케어 지출 증가는 호흡곤란 시장의 성장에 기여하는 또 다른 중요한 요인입니다. 헬스케어 지출에는 병원 치료, 의약품, 예방 치료에 대한 공적 및 사적 지출을 포함한 의료 서비스에 지출되는 총 재원이 포함됩니다. 헬스케어 지출의 증가는 고도의 치료에 대한 수요 고조, 고령화, 장기적인 케어 및 고액의 개입을 필요로 하는 만성 질환 부담 증가가 배경에 있습니다. 투자액의 증가는 흡입기, 산소요법, 생물제제 등의 신규 치료법의 개발 및 이용을 촉진하여 환자의 전귀 개선으로 이어집니다. 게다가 지출의 증가는 헬스케어 인프라와 전문 의료를 강화하고 호흡곤란과 관련된 질환의 조기 진단과 효과적인 관리를 가능하게 합니다. 예를 들어 2023년 12월 미국 연방정부기관인 메디케어 & 메디케이드 서비스센터는 2022년 미국의 의료비가 4.1% 증가한 4조 5,000억 달러에 달했으며, 2021년 기록된 3.2% 증가를 웃돌았다고 보고했습니다. 그 결과 의료 지출의 증가가 호흡곤란 시장의 성장을 뒷받침하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 호흡곤란 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 호흡곤란 시장 : 성장률 분석
- 세계의 호흡곤란 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 호흡곤란 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 호흡곤란 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 호흡곤란 시장 : 치료 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 보조산소요법
- 릴렉제이션 테라피
- 세계의 호흡곤란 시장 : 약제 클래스별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 항불안
- 항생제
- 항콜린제
- 코르티코스테로이드
- 기타 약물 클래스
- 세계의 호흡곤란 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 오랄
- 흡입
- 기타 투여 경로
- 세계의 호흡곤란 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 홈케어
- 전문 클리닉
- 외래 서비스
- 기타 최종 사용자
- 세계의 호흡곤란 시장 : 산소 보급 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 지속흐름 산소요법
- 펄스 산소요법
- 산소 농축기
- 휴대용 산소 실린더
- 세계의 호흡곤란 시장 : 릴렉제이션 치료 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 호흡법
- 명상 및 마인드풀니스
- 점진적 근육 이완법
- 바이오 피드백 요법
제7장 지역별 및 국가별 분석
- 세계의 호흡곤란 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 호흡곤란 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 호흡곤란 시장 : 경쟁 구도
- 호흡곤란 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- F. Hoffmann-La Roche Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck And Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Bayer AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- AstraZeneca
- Novartis AG
- GlaxoSmithKline
- Amgen Inc.
- Viatris Inc
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim
- Amneal Pharmaceuticals LLC
- Lupin Ltd
- Lincare Holdings Inc
- Nephron Pharmaceuticals Corporation
- Rotech Healthcare Inc.
- Inogen Inc
- Lannett Inc.
- Ligand Pharmaceuticals Incorporated
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 호흡곤란 시장(2029년) : 새로운 기회를 제공하는 국가
- 호흡곤란 시장(2029년) : 새로운 기회를 제공하는 부문
- 호흡곤란 시장(2029년) : 성장 전략
제36장 부록
AJY
Dyspnea refers to difficulty breathing or shortness of breath, describing the sensation of not getting enough air into the lungs. It can present as chest tightness, gasping for air, or increased effort to breathe. Various clinical methods and tools are used to assess its severity, impact on daily life, and underlying causes.
The primary treatment options for dyspnea include supplemental oxygen therapy and relaxation therapy. Supplemental oxygen therapy involves delivering oxygen to improve blood oxygen levels, assisting patients with respiratory conditions or those recovering from severe illnesses. The drug classes used for treatment include anti-anxiety medications, antibiotics, anticholinergic agents, corticosteroids, and others. These medications are administered through various routes, such as oral, inhalation, and other methods. Dyspnea treatments are utilized across different healthcare settings, including hospitals, home care, specialty clinics, ambulatory services, and other medical facilities.
The dyspnea market research report is one of a series of new reports from The Business Research Company that provides dyspnea market statistics, including the dyspnea industry global market size, regional shares, competitors with the dyspnea market share, detailed dyspnea market segments, market trends, and opportunities, and any further data you may need to thrive in the dyspnea industry. This dyspnea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The dyspnea market size has grown strongly in recent years. It will grow from $6.26 billion in 2024 to $6.75 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to increasing awareness of respiratory diseases, the rising incidence of lifestyle-related factors, the expanding geriatric population, a surge in clinical trials, and growing supportive government initiatives.
The dyspnea market size is expected to see strong growth in the next few years. It will grow to $8.97 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth during the forecast period can be attributed to the increasing prevalence of chronic diseases, rising demand for personalized medicine, worsening pollution levels, greater adoption of telemedicine, and the implementation of more favorable regulations. Key trends in the forecast period include strategic collaborations, technological advancements, the development of novel inhalers, the expansion of personalized medicine, and the rise of targeted therapies.
The rising prevalence of respiratory diseases is expected to drive the growth of the dyspnea market in the coming years. Respiratory diseases affect the lungs and other parts of the respiratory system, leading to difficulty in breathing and impaired oxygen exchange. Common conditions include asthma, chronic obstructive pulmonary disease (COPD), and tuberculosis (TB). The increase in respiratory diseases is attributed to factors such as air pollution, smoking, exposure to environmental toxins, and climate change. Dyspnea plays a key role in diagnosing and managing respiratory conditions by indicating lung function impairment, guiding treatment strategies, and monitoring disease progression. For example, in November 2023, the National Asthma Council, an Australia-based non-profit organization, reported that in 2022, Australia recorded 467 asthma-related deaths, an increase from 355 deaths in 2021 including 299 females and 168 males. As a result, the growing prevalence of respiratory diseases is fueling the expansion of the dyspnea market.
The rise in healthcare expenditure is another key factor contributing to the growth of the dyspnea market. Healthcare expenditure encompasses total financial resources spent on medical services, including public and private spending on hospital care, pharmaceuticals, and preventive treatments. The increasing healthcare expenditure is driven by the rising demand for advanced medical treatments, an aging population, and the growing burden of chronic diseases that require long-term care and costly interventions. Higher investments facilitate the development and accessibility of novel therapies, such as inhalers, oxygen therapy, and biologics, leading to improved patient outcomes. Additionally, increased spending enhances healthcare infrastructure and specialized care, enabling early diagnosis and effective management of dyspnea-related conditions. For instance, in December 2023, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, surpassing the 3.2% growth recorded in 2021. Consequently, rising healthcare expenditure is supporting the growth of the dyspnea market.
Leading companies in the dyspnea market are focusing on the development of innovative treatments, such as phosphodiesterase (PDE) inhibitors, to enhance therapeutic efficacy and provide improved relief for patients with respiratory conditions. PDE inhibitors work by blocking the activity of phosphodiesterase enzymes, increasing cyclic AMP or cyclic GMP levels in cells, which can enhance vasodilation, reduce inflammation, or improve cardiac function. For example, in May 2024, Verona Pharma Plc, a UK-based biopharmaceutical company, announced its plans for the anticipated U.S. launch of ensifentrine, a first-in-class dual PDE 3/4 inhibitor for COPD treatment, in Q3 2024, pending FDA approval. Ensifentrine, a nebulized treatment for COPD, has demonstrated significant reductions in exacerbation rates and improvements in dyspnea in Phase III clinical trials. The company has secured $650 million in financing to support the drug's commercial launch and ongoing development, including a planned Phase II trial for a fixed-dose combination with glycopyrrolate as a maintenance therapy for COPD patients.
Major players in the dyspnea market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca, Novartis AG, GlaxoSmithKline, Amgen Inc., Viatris Inc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Amneal Pharmaceuticals LLC, Lupin Ltd, Lincare Holdings Inc, Nephron Pharmaceuticals Corporation, Rotech Healthcare Inc., Inogen Inc, Lannett Inc., Ligand Pharmaceuticals Incorporated, OMRON Healthcare Inc, Flexicare Medical Ltd, Zydus Cadila Healthcare Ltd, Advacare Pharma, Airways surgical Pvt. Ltd., Belluscura Plc.
North America was the largest region in the dyspnea market in 2024. Asia pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dyspnea report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the dyspnea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dyspnea market consists of revenues earned by entities by providing services such as pulmonary rehabilitation, oxygen therapy, respiratory monitoring, telemedicine consultations, and patient education programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The dyspnea market also includes sales of products such as bronchodilators, ventilators, nebulizers, portable oxygen concentrators, and pulmonary function testing devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The IT market is segmented into IT services, computer hardware, telecom, and software products.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption. values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dyspnea Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dyspnea market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dyspnea ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dyspnea market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Supplemental Oxygen Therapy; Relaxation Therapy
- 2) By Drug Class: Antianxiety; Antibiotics; Anticholinergic Agents; Corticosteroids; Other Drug Classes
- 3) By Route Of Administration: Oral; Inhalation; Other Route Of Administrations
- 4) By End User: Hospitals; Homecare; Specialty Clinics; Ambulatory Services; Other End Users
- Subsegments:
- 1) By Supplemental Oxygen Therapy: Continuous Flow Oxygen Therapy; Pulse Dose Oxygen Therapy; Oxygen Concentrators; Portable Oxygen Cylinders
- 2) By Relaxation Therapy: Breathing Exercises; Meditation and Mindfulness; Progressive Muscle Relaxation; Biofeedback Therapy
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck And Co. Inc.; Bayer AG; Sanofi S.A.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Dyspnea Market Characteristics
3. Dyspnea Market Trends And Strategies
4. Dyspnea Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Dyspnea Growth Analysis And Strategic Analysis Framework
- 5.1. Global Dyspnea PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Dyspnea Market Growth Rate Analysis
- 5.4. Global Dyspnea Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Dyspnea Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Dyspnea Total Addressable Market (TAM)
6. Dyspnea Market Segmentation
- 6.1. Global Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Supplemental Oxygen Therapy
- Relaxation Therapy
- 6.2. Global Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antianxiety
- Antibiotics
- Anticholinergic Agents
- Corticosteroids
- Other Drug Classes
- 6.3. Global Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Inhalation
- Other Route Of Administrations
- 6.4. Global Dyspnea Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Ambulatory Services
- Other End Users
- 6.5. Global Dyspnea Market, Sub-Segmentation Of Supplemental Oxygen Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Continuous Flow Oxygen Therapy
- Pulse Dose Oxygen Therapy
- Oxygen Concentrators
- Portable Oxygen Cylinders
- 6.6. Global Dyspnea Market, Sub-Segmentation Of Relaxation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Breathing Exercises
- Meditation and Mindfulness
- Progressive Muscle Relaxation
- Biofeedback Therapy
7. Dyspnea Market Regional And Country Analysis
- 7.1. Global Dyspnea Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Dyspnea Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Dyspnea Market
- 8.1. Asia-Pacific Dyspnea Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Dyspnea Market
- 9.1. China Dyspnea Market Overview
- 9.2. China Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Dyspnea Market
- 10.1. India Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Dyspnea Market
- 11.1. Japan Dyspnea Market Overview
- 11.2. Japan Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Dyspnea Market
- 12.1. Australia Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Dyspnea Market
- 13.1. Indonesia Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Dyspnea Market
- 14.1. South Korea Dyspnea Market Overview
- 14.2. South Korea Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Dyspnea Market
- 15.1. Western Europe Dyspnea Market Overview
- 15.2. Western Europe Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Dyspnea Market
- 16.1. UK Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Dyspnea Market
- 17.1. Germany Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Dyspnea Market
- 18.1. France Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Dyspnea Market
- 19.1. Italy Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Dyspnea Market
- 20.1. Spain Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Dyspnea Market
- 21.1. Eastern Europe Dyspnea Market Overview
- 21.2. Eastern Europe Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Dyspnea Market
- 22.1. Russia Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Dyspnea Market
- 23.1. North America Dyspnea Market Overview
- 23.2. North America Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Dyspnea Market
- 24.1. USA Dyspnea Market Overview
- 24.2. USA Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Dyspnea Market
- 25.1. Canada Dyspnea Market Overview
- 25.2. Canada Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Dyspnea Market
- 26.1. South America Dyspnea Market Overview
- 26.2. South America Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Dyspnea Market
- 27.1. Brazil Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Dyspnea Market
- 28.1. Middle East Dyspnea Market Overview
- 28.2. Middle East Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Dyspnea Market
- 29.1. Africa Dyspnea Market Overview
- 29.2. Africa Dyspnea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Dyspnea Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Dyspnea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Dyspnea Market Competitive Landscape And Company Profiles
- 30.1. Dyspnea Market Competitive Landscape
- 30.2. Dyspnea Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
31. Dyspnea Market Other Major And Innovative Companies
- 31.1. AstraZeneca
- 31.2. Novartis AG
- 31.3. GlaxoSmithKline
- 31.4. Amgen Inc.
- 31.5. Viatris Inc
- 31.6. Teva Pharmaceutical Industries Ltd.
- 31.7. Boehringer Ingelheim
- 31.8. Amneal Pharmaceuticals LLC
- 31.9. Lupin Ltd
- 31.10. Lincare Holdings Inc
- 31.11. Nephron Pharmaceuticals Corporation
- 31.12. Rotech Healthcare Inc.
- 31.13. Inogen Inc
- 31.14. Lannett Inc.
- 31.15. Ligand Pharmaceuticals Incorporated
32. Global Dyspnea Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Dyspnea Market
34. Recent Developments In The Dyspnea Market
35. Dyspnea Market High Potential Countries, Segments and Strategies
- 35.1 Dyspnea Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Dyspnea Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Dyspnea Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
